Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
US9234025B2 · kind B2 · utility
0Cited by
1References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 2, 2010 |
| Grant date | Jan 12, 2016 |
| Priority date | — |
| Expiry date | Jan 6, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.